ELI LILLY & Co (LLY) stock
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 19/3025% above fair value
$1415.55−16.12 (-1.13%)
Close on Nov 17, 2026Market cap $1.33TP/E 45.9Yield 0.44%
Eli Lilly pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Eli Lilly's pe ratio was 48.2× on Nov 11, 2026, against 52.6× a year earlier. Over the last 5 years it ranged from 37.4× to 134.7×, with a median of 56.4×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 48.2× | −4.3 |
| 2025 | Dec 31, 2025 | 52.6× | −30.9 |
| 2024 | Dec 31, 2024 | 83.5× | −22.1 |
| 2023 | Dec 29, 2023 | 105.6× | +50.6 |
| 2022 | Dec 30, 2022 | 55.0× | +12.9 |
| 2021 | Dec 31, 2021 | 42.1× | +14.5 |
| 2020 | Dec 31, 2020 | 27.6× | +11.6 |
| 2019 | Dec 31, 2019 | 16.0× | −241.2 |
| 2018 | Dec 31, 2018 | 257.2× | +217.1 |
| 2017 | Dec 29, 2017 | 40.0× | +8.0 |
| 2016 | Dec 30, 2016 | 32.0× | −6.1 |
| 2015 | Dec 31, 2015 | 38.1× | +22.2 |
| 2014 | Dec 31, 2014 | 16.0× | +2.2 |
| 2013 | Jan 31, 2013 | 13.8× | +1.1 |
| 2012 | Dec 31, 2012 | 12.6× | – |
See a number that looks wrong?